Skip to main content
. 2015 Nov 7;108(2):djv313. doi: 10.1093/jnci/djv313

Figure 1.

Figure 1.

Differential response of human epidermal growth factor receptor 2 (HER2)–positive breast cancer lesions to trastuzumab or T-DM1 in the central nervous system (CNS) microenvironment. BT474-Gluc (A) and MDA-MB-361-Gluc (B) tumors growing in the brain were treated with trastuzumab or T-DM1 (15mg/kg), and blood Gluc activity (relative light units per sec [RLU/s]) was measured over time. Nonspecific human IgG was used as control at the same dose (n = 9–11). C) Cranial windows were placed to monitor BT474-Gluc tumor volume. Representative images of size- and time-matched BT474-Gluc tumors 24 days after treatment initiation. D) Representative ultrasonography images of size- and time-matched BT474-Gluc tumors treated with trastuzumab or T-DM1 (15mg/kg) at day 0 and day 24. E) Corresponding three-dimensional reconstruction of tumor volume. The Gaussia luciferase activity measured from blood samples correlates with tumor volume. RLU = relative light unit.